Search results for "leukemia"

showing 10 items of 976 documents

Spatiotemporal distribution of gp130 cytokines and their receptors after status epilepticus: comparison with neuronal degeneration and microglial act…

2003

Although numerous studies have demonstrated the neurotrophic capacity of gp130 cytokines, it remains unclear whether endogenously expressed cytokines actually function in a direct neuromodulatory manner. Therefore, using the lithium-pilocarpine status epilepticus model, we performed a detailed in situ hybridization time-course study of five gp130 cytokines (interleukin [IL]-6, leukemia inhibitory factor [LIF], IL-11, oncostatin-m [OSM], and ciliary neurotrophic factor), gp130, and the receptors of the cytokines we found to be induced (IL-6 receptor [IL-6R], LIF receptor [LIF-R], and IL-11 receptor [IL-11R]). Additionally, to further understand the regulation of these cytokines, we compared …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentBiologyHippocampal formationHippocampusRats Sprague-DawleyStatus EpilepticusInternal medicinemedicineAnimalsReceptors CytokineReceptorMicrogliaGeneral NeuroscienceDentate gyrusGlycoprotein 130Granule cellRatsmedicine.anatomical_structureEndocrinologyCytokineNerve DegenerationCytokinesMicrogliaLeukemia inhibitory factorSignal TransductionNeuroscience
researchProduct

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent…

2015

Summary Background Acute myeloid leukaemia mainly affects elderly people, with a median age at diagnosis of around 70 years. Although about 50–60% of patients enter first complete remission upon intensive induction chemotherapy, relapse remains high and overall outcomes are disappointing. Therefore, effective post-remission therapy is urgently needed. Although often no post-remission therapy is given to elderly patients, it might include chemotherapy or allogeneic haemopoietic stem cell transplantation (HSCT) following reduced-intensity conditioning. We aimed to assess the comparative value of allogeneic HSCT with other approaches, including no post-remission therapy, in patients with acute…

Malemedicine.medical_specialtyTransplantation ConditioningGemtuzumab ozogamicinmedicine.medical_treatmentAntibodies Monoclonal HumanizedCOUNCIL AML11 TRIALEUROPEAN LEUKEMIANETInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointINDUCTION CHEMOTHERAPYHumansTransplantation HomologousProspective StudiesADULT PATIENTS610 Medicine & healthBusulfanMETAANALYSISAgedMYELODYSPLASTIC SYNDROMEChemotherapyRISK-ADAPTED APPROACHbusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInduction chemotherapyHematology1ST COMPLETE REMISSIONTotal body irradiationMiddle AgedGemtuzumabGEMTUZUMAB OZOGAMICINSurgeryFludarabineTransplantationSurvival RateLeukemia Myeloid AcuteAminoglycosidesTreatment OutcomeSURVIVALFemaleNeoplasm Recurrence LocalbusinessBusulfanVidarabinemedicine.drugLancet. Haematology
researchProduct

Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors

2018

Vitamin D (25-OHD) has a role in bone health after treatment for cancer. 25-OHD deficiency has been associated with risk factors for cardiovascular disease, but no data focusing on this topic in childhood cancer survivors have been published. We investigated the 25-OHD status in children treated for acute lymphoblastic leukemia (ALL), and evaluated its influence on vascular function. 25-OHD levels were evaluated in 52 ALL survivors and 40 matched healthy controls. Patients were grouped according to 25-OHD level (< 20 ng/m or ≥ 20 ng/ml). Auxological parameters, biochemical and hemostatic markers of endothelial function (AD, HMW-AD, ET-1, vWFAg, TAT, D-dimers, Fbg, and hs-CRP), ultrasound ma…

Malemedicine.medical_specialtyendocrine system diseasesAdolescentDiseaseAcute lymphoblastic leukemiaurologic and male genital diseasesGastroenterologyC-IMT03 medical and health sciencesYoung Adult0302 clinical medicineRisk Factors030225 pediatricsmedicine.arteryInternal medicinePediatric surgerymedicineVitamin D and neurologyHumans030212 general & internal medicineSurvivorsVitamin DChildChildhood Acute Lymphoblastic LeukemiaUnivariate analysisbusiness.industryAbdominal aortaConfoundingnutritional and metabolic diseasesCancerPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVitamin D DeficiencyCardiovascular diseaseChild PreschoolPediatrics Perinatology and Child HealthFemaleEndothelium VascularbusinessBiomarkersVascular ultrasound studie
researchProduct

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogenei…

2021

Objective To compare the efficacy and safety of CD34+ selected ex vivo T-cell depletion (TCD) vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil (PTCy-Sir-MMF) as graft-vs-host disease (GVHD) prophylaxis. Methods We retrospectively included patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) with either TCD (n = 38) or PTCy-Sir-MMF (n = 91). Results Cumulative incidence of neutrophil and platelet recovery was 92% vs 99% (P = .06) and 89% vs 97% (P = .3) in TCD and PTCy-Sir-MMF, respectively. Cumulative incidences of aGHVD grade II-IV, III-IV, and moderate to severe cGVHD were 11% vs 19% (P = .2), 3% vs 2% (P = .9), and 3% vs 36% (P < …

Malemedicine.medical_treatmentT-LymphocytesCD34Graft vs Host DiseaseHematopoietic stem cell transplantationMycophenolateGastroenterologySeverity of Illness IndexLeukocyte Count0302 clinical medicineImmune ReconstitutionPostoperative ComplicationsRecurrenceGVHD prophylaxisAntineoplastic Combined Chemotherapy ProtocolsCumulative incidenceHematopoietic Stem Cell TransplantationT-cell depletionHematologyGeneral MedicineMiddle AgedPrognosisLeukemia Myeloid Acutesurgical procedures operativeTreatment OutcomeT-cell depletion030220 oncology & carcinogenesishematopoietic stem cell transplantationcardiovascular systemFemalemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideAdolescentLymphocyte Depletion03 medical and health sciencesYoung AdultInternal medicinemedicineHumansTransplantation HomologousGVHD prophylaxis T-cell depletion hematopoietic stem cell transplantation post-transplantation cyclophosphamideCyclophosphamideAgedPostoperative CareSirolimuspost-transplantation cyclophosphamidebusiness.industryMycophenolic AcidSirolimusbusinessEx vivoBiomarkers030215 immunologyEuropean journal of haematologyREFERENCES
researchProduct

Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies

2015

Sara Capolla,1 Chiara Garrovo,2 Sonia Zorzet,1 Andrea Lorenzon,3 Enrico Rampazzo,4 Ruben Spretz,5 Gabriele Pozzato,6 Luis N&amp;uacute;&amp;ntilde;ez,7 Claudio Tripodo,8 Paolo Macor,1,9 Stefania Biffi2 1Department of Life Sciences, University of Trieste, 2Institute for Maternal and Child Health &amp;ndash; IRCCS &amp;ldquo;Burlo Garofolo&amp;rdquo;, Trieste, 3Animal Care Unit, Cluster in Biomedicine (CBM scrl), Trieste, Italy; 4Department of Chemistry &amp;ldquo;G. Ciamician&amp;rdquo;, University of Bologna, Bologna, Italy; 5LNK Chemsolutions LLC, Lincoln, NE, USA; 6Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 7Bio-Target, Inc., University of C…

Medicine (General)Active targeting; Optical imaging; Tumor accumulation; Animals; Antigens CD20; Cell Line Tumor; Humans; Leukemia B-Cell; Mice; Molecular Imaging; Nanoparticles; Polymers; Drug Delivery Systems; Bioengineering; Biophysics; Biomaterials; Drug Discovery3003 Pharmaceutical Science; Organic ChemistryTumor accumulationPolymersPharmaceutical SciencePharmacologyOptical imagingMiceDrug Delivery SystemsNanoparticleInternational Journal of NanomedicineDrug DiscoveryPolymerOriginal ResearchActive targeting; Optical imaging; Tumor accumulation; Animals; Antigens CD20; Cell Line Tumor; Humans; Leukemia B-Cell; Mice; Molecular Imaging; Nanoparticles; Polymers; Drug Delivery Systems; Biophysics; Bioengineering; Biomaterials; Organic Chemistry; Drug Discovery3003 Pharmaceutical ScienceTumorLeukemiaActive targetingtumor accumulationGeneral MedicineMolecular ImagingDrug deliverySystemic administrationPreclinical imagingHumanactive targetingMaterials scienceBiophysicsBioengineeringCell LineBiomaterialsoptical imagingR5-920In vivoCell Line TumormedicineLeukemia B-CellDistribution (pharmacology)AnimalsHumansCD20AntigensAnimalDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryB-CellCancermedicine.diseaseAntigens CD20BiomaterialTargeted drug deliveryBiophysicNanoparticlesMolecular imagingDrug Delivery System
researchProduct

CD28, a marker associated with tumoral expansion in multiple myeloma

1998

International audience; CD28 expression was thoroughly investigated on plasma cells of monoclonal gammopathy of undetermined significance, multiple myeloma (MM), and human myeloma cell lines. CD28+ plasma cells were detected in 19% of 31 monoclonal gammopathy of undetermined significance, 41% of 116 MM, and 100% of 13 human myeloma cell lines. CD28+ myeloma cells were detected in 21 of 79 (26%) MM cases at diagnosis, 13 of 22 (59%) at medullary relapse (P < 0.009), and 14 of 15 (93%) at extramedullary relapse (P = 0.05), including 10 of 10 (100%) secondary plasma cell leukemias (P = 0.05). Serial studies in individual patients confirmed the emergence of CD28+ myeloma cells with tumoral expa…

Membrane GlycoproteinsParaproteinemiasNeoplasms Second Primarychemical and pharmacologic phenomenahemic and immune systemsCD56 AntigenCell LineLeukemia Plasma CellCD28 AntigensAntigens CDBone MarrowPredictive Value of TestsRecurrence[ INFO.INFO-BI ] Computer Science [cs]/Bioinformatics [q-bio.QM]hemic and lymphatic diseasesB7-1 AntigenBiomarkers TumorDisease ProgressionTumor Cells CulturedHumansB7-2 AntigenTreatment Failure[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]Multiple Myeloma[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM]
researchProduct

Bioactive metabolites from the endophytic fungus Ampelomyces sp. isolated from the medicinal plant Urospermum picroides

2007

Extracts of cultures grown in liquid or on solid rice media of the fungal endophyte Ampelomyces sp. isolated from the medicinal plant Urospermum picroides exhibited considerable cytotoxic activity when tested in vitro against L5178Y cells. Chromatographic separation yielded 14 natural products that were unequivocally identified based on their 1H and 13C NMR as well as mass spectra and comparison with previously published data. Six compounds (2, 4, 5, 7, 9 and 11) were natural products. Both fungal extracts differed considerably in their secondary metabolites. The extract obtained from liquid cultures afforded a pyrone (2) and sulfated anthraquinones (7 and 9) along with the known compounds …

MetaboliteMicrobial Sensitivity TestsPlant ScienceAsteraceaeHorticultureBiochemistryEndophyteGas Chromatography-Mass SpectrometryEnterococcus faecalisPlant use of endophytic fungi in defenseMicrobiologyMicechemistry.chemical_compoundAnti-Infective AgentsAscomycotaCell Line TumorAnthraquinonesAnimalsFood scienceLeukemia L5178Urospermum picroidesMolecular BiologyPlants MedicinalBacteriaMolecular StructurebiologyCytotoxinsGeneral MedicineAntimicrobialbiology.organism_classificationPyronechemistryDrug Screening Assays AntitumorPhytochemistry
researchProduct

MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells

2022

Abstract Chronic lymphocytic leukemia (CLL) cells express the interleukin-23 receptor (IL-23R) chain, but the expression of the complementary IL-12Rβ1 chain requires cell stimulation via surface CD40 molecules (and not via the B-cell receptor [BCR]). This stimulation induces the expression of a heterodimeric functional IL-23R complex and the secretion of IL-23, initiating an autocrine loop that drives leukemic cell expansion. Based on the observation in 224 untreated Binet stage A patients that the cases with the lowest miR-146b-5p concentrations had the shortest time to first treatment (TTFT), we hypothesized that miR-146b-5p could negatively regulate IL-12Rβ1 side chain expression and clo…

MiceMicroRNAsCD40 LigandAnimalsReceptors Antigen B-CellChronic lymphocytic leukemia interleukin-23 receptor (IL-23R) MiR-146bSettore MED/05 - Patologia ClinicaRNA MessengerHematologySettore MED/08 - Anatomia PatologicaInterleukin-23Leukemia Lymphocytic Chronic B-CellBlood Advances
researchProduct

Factors Determining Sensitivity and Resistance of Tumor Cells to Arsenic Trioxide

2012

Previously, arsenic trioxide showed impressive regression rates of acute promyelocytic leukemia. Here, we investigated molecular determinants of sensitivity and resistance of cell lines of different tumor types towards arsenic trioxide. Arsenic trioxide was the most cytotoxic compound among 8 arsenicals investigated in the NCI cell line panel. We correlated transcriptome-wide microarray-based mRNA expression to the IC(50) values for arsenic trioxide by bioinformatic approaches (COMPARE and hierarchical cluster analyses, Ingenuity signaling pathway analysis). Among the identified pathways were signaling routes for p53, integrin-linked kinase, and actin cytoskeleton. Genes from these pathways…

MicroarraysTumor PhysiologyCancer Treatmentlcsh:MedicineToxicologyArsenicalschemistry.chemical_compoundArsenic TrioxideBasic Cancer ResearchRNA NeoplasmArsenic trioxidelcsh:ScienceOligonucleotide Array Sequence AnalysisMultidisciplinaryintegumentary systemCytotoxinsOxidesTransfectionNeoplasm ProteinsGene Expression Regulation NeoplasticActin CytoskeletonOncologyMedicineThioredoxinSignal TransductionResearch Articleinorganic chemicalsAcute promyelocytic leukemiaToxic Agentschemistry.chemical_elementAntineoplastic AgentsBiologyComplementary and Alternative MedicineCell Line TumormedicineHumansRNA MessengerBiologyArseniclcsh:RComputational BiologyCancers and Neoplasmsmedicine.diseaseActin cytoskeletonMolecular biologychemistryDrug Resistance NeoplasmApoptosisCell culturelcsh:QPLoS ONE
researchProduct

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

2007

Summary Objectives Invasive fungal infections remain a frequent cause of morbidity and mortality in long-term neutropenic patients. The availability of tolerable broad-spectrum antifungals like voriconazole stimulated the discussion about optimal timing of antifungal therapy. We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML). Methods This was a prospective, randomised, double-blind, placebo-controlled phase III trial in AML patients undergoing remission induction chemotherapy. Oral voriconazole 200mg twice daily or placebo was administered until detection of a lung…

Microbiology (medical)AdultMalePosaconazolemedicine.medical_specialtyAntifungal AgentsAdolescentAdministration OralNeutropeniaPlacebolaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansProspective StudiesAgedVoriconazoleLeukopeniaLung Diseases Fungalbusiness.industryIncidenceInduction chemotherapyLength of StayMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesPyrimidinesMycosesFemaleVoriconazolemedicine.symptombusinessmedicine.drugThe Journal of infection
researchProduct